News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Second-Generation Stent Superior in Clinical Endpoints, Columbia University Study



5/6/2010 7:32:58 AM

MedPage Today -- The everolimus-eluting Xience stent appears superior to the paclitaxel-eluting Taxus stent based on the clinical endpoint of target lesion failure, according to findings from the SPIRIT-IV trial.

Read at MedPageToday
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES